Amr Conventions Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$13,036	6
2023	Research	$178,460	22
2022	Research	$57,993	5
2021	Research	$44,384	4
2020	Research	$110,919	16
2019	Research	$22,820	2

Breakdown

Who paid Research payments · program years 2019–2024

F. Hoffmann-La Roche AG $184,354 15 payments
Supernus Pharmaceuticals, Inc. $135,367 15 payments
Sumitomo Pharma America, Inc. $64,599 17 payments
H. Lundbeck A S $43,290 8 payments

Studies the money was for Research payments · program years 2019–2024

P2 Study of Balovaptan in PTSD $184,354 15 payments
Open-Label Extension Study to Evaluate the Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder $87,592 8 payments
A 24-Week Open-Label Study Evaluating the Effectiveness Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia Switched from Typical or Atypical Antipsychotic Agents OLE. $51,564 11 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) in Conjunction With Standard Adhd Treatment $30,056 3 payments
Assessment of Efficacy and Safety of Spn-810 for the Treatment of Impulsive Aggression (Ia) in Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (Adhd) in Conjunction With Standard Adhd Treatment $17,719 4 payments
Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder MDD $15,294 1 payment
Active Reference (Fluoxetine) Fixed-Dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) $10,774 4 payments
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) $9,696 2 payments
Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder MDD $7,526 1 payment
A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression) $7,517 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.